CorMedix Inc Current Ratio 2011-2021 | CRMD

CorMedix Inc current ratio from 2011 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CorMedix Inc Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.08B $0.00B 25.52
2021-03-31 $0.08B $0.00B 27.24
2020-12-31 $0.05B $0.00B 11.58
2020-09-30 $0.04B $0.01B 8.45
2020-06-30 $0.02B $0.01B 4.22
2020-03-31 $0.03B $0.01B 4.70
2019-12-31 $0.03B $0.01B 5.04
2019-09-30 $0.03B $0.01B 6.71
2019-06-30 $0.03B $0.00B 6.31
2019-03-31 $0.03B $0.00B 6.26
2018-12-31 $0.02B $0.01B 2.40
2018-09-30 $0.01B $0.02B 0.45
2018-06-30 $0.01B $0.01B 0.46
2018-03-31 $0.01B $0.01B 1.07
2017-12-31 $0.01B $0.01B 2.12
2017-09-30 $0.01B $0.00B 3.26
2017-06-30 $0.02B $0.01B 3.64
2017-03-31 $0.02B $0.00B 3.82
2016-12-31 $0.02B $0.00B 5.34
2016-09-30 $0.03B $0.01B 5.71
2016-06-30 $0.03B $0.00B 10.00
2016-03-31 $0.03B $0.00B 10.96
2015-12-31 $0.04B $0.00B 12.11
2015-09-30 $0.04B $0.00B 13.63
2015-06-30 $0.04B $0.00B 20.27
2015-03-31 $0.01B $0.00B 4.57
2014-12-31 $0.01B $0.00B 3.53
2014-09-30 $0.01B $0.00B 5.53
2014-06-30 $0.01B $0.00B 6.94
2014-03-31 $0.01B $0.00B 8.65
2013-12-31 $0.00B $0.00B 1.74
2013-09-30 $0.00B $0.00B 0.26
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.59
2012-09-30 $0.00B $0.00B 0.90
2012-06-30 $0.00B $0.00B 0.86
2012-03-31 $0.00B 0.00
2011-12-31 $0.00B $0.00B 1.95
2011-09-30 $0.00B $0.00B 1.32
2011-06-30 $0.01B $0.00B 2.89
2011-03-31 $0.01B $0.00B 4.71
2010-12-31 $0.01B $0.00B 5.61
2010-09-30 $0.01B $0.00B 10.42
2010-06-30 $0.01B $0.00B 9.52
2010-03-31 $0.01B $0.00B 8.46
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.177B $0.000B
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71